CompanyBioInvent International AB
Sweden
BioInvent is a research-based pharmaceutical company developing innovative antibody drugs to target diseases with unmet clinical need. The companyÂ’s strategy is to leverage its expertise in antibodies and cancer biology to develop immuno-oncology drugs that significantly improve the treatment of cancer diseases and prolong cancer patients' lives.
Private/Public:
public
Phone:+46 (0)46-286 85 50
Fax:+46 (0)46-211 08 06
Email:[email protected]
Website:http://www.bioinvent.com/
Address:Ideon Science Park SE-223 70 Lund, Sweden
1996
Since
1
Country
7
Top Service Categories
57
Sub-Service Categories
Top Services
Analytical
Analytical lab services
Discovery and Preclinical
Specific Services-Discovery
Microbiology
Specific Services - microbiology
API/Biologicals Production
API/Biologics development and manufacturing
Formulation
Formulation development related
Formulation types
Bioanalytical
Bioanalytical assays
| Facility type | Address | Telephone | Fax | City | State code | Country | Service categories |
|---|---|---|---|---|---|---|---|
| Global Corporate Headquarters | Ideon Science Park SE-223 70 Lund | +46 (0)46-286 85 50 | +46 (0)46-211 08 06 | Lund | Sweden |
- (28.May.2020) Resolutions at BioInvent's Annual General Meeting 2020
- (15.May.2020) BioInvent and Transgene Present Preclinical Data Demonstrating BT-001's Powerful Activity Against Solid Tumors
- (15.May.2020) BioInvent Expands Anti-TNFR2 Program by Selecting Second Monoclonal Antibody for Further Deveplopment
- (30.Apr.2020) BioInvent Signs New Manufacturing Agreement With U.S. Cell Therapy Company
- (28.Apr.2020) BioInvent Interim Report January 1 - March 31, 2020
- (14.Apr.2020) BioInvent Reports Promising Progress in Phase I/Ila Trial of Lead Program BI-1206 in Combination With Rituximab
- (26.Mar.2020) BioInvent Postpones the Annual General Meeting and Provides an Update on the Current Situation in Respect of COVID-19
- (24.Mar.2020) SkylineDx and BioInvent to Collaborate on Patient Stratification to Maximize Impact of Treatment with BI-1206
- (03.Mar.2020) Transgene and BioInvent to Present Data on BT-001, an Oncolytic Virus Encoding for an Anti-CTLA4 Antibody, at Upcoming Congresses
- (27.Feb.2020) BioInvent Financial Statement January 1 - December 31, 2019
- (23.Dec.2019) BioInvent Announces Selection of Second Target and Extension of the Research Collaboration and License Agreement With Pfizer Inc
- (18.Dec.2019) BioInvent Has Entered Into a Clinical Trial Collaboration and Supply Agreement to Evaluate BI-1206 in Combination With KEYTRUDA in Advanced Solid Tumors
- (13.Dec.2019) Abcentra Announces Achievement of Manufacturing Milestone for Upcoming Clinical Trial
- (11.Dec.2019) BioInvent and Transgene Announce Compelling Preclinical Data for BT-001 in Solid Tumors
- (08.Nov.2019) BioInvent to Present BI-1206 Preclinical Data in Mantle Cell Lymphoma at ASH 2019
- (24.Oct.2019) Interim Report January 1 – September 30, 2019
- (23.Oct.2019) BioInvent Signs Manufacturing Agreement With Cancer Research UK Expected to Generate Approximately SEK 30 Million (~$3 Million)
- (22.Aug.2019) BioInvent: Interim Report January 1 - June 30, 2019
- (21.Aug.2019) BioInvent Will Conduct Phase I/IIa Trial With BI-1206 in Combination With Pembrolizumab (Keytruda) in Solid Tumors
- (20.Aug.2019) Oxurion NV Reports Topline Month 3 Results of Phase 2a Study Evaluating THR-317 (Anti-Plgf), in Combination With Ranibizumab, for DME
- (15.Aug.2019) USPTO Intends to Grant BioInvent Patent Relating to BI-1206
- (31.Jul.2019) BioInvent Announces Selection of First Target Discovered by BioInvent's Proprietary F.I.R.S.T Technology Platform Under Collaboration With Pfizer Inc
- (04.Jul.2019) BioInvent Receives Milestone Payment Related to TAK-169 Investigational New Drug Application
- (02.Jul.2019) Bioinvent Receives Ind Approval for Phase I/IIa Trial of Anti-Fcγriib Antibody
- (28.Jun.2019) Change in the Number of Shares and Votes in BioInvent International AB
- (12.Jun.2019) BioInvent Publishes First Clinical Data From BI-1206 Phase I/IIa Trials
- (03.Jun.2019) BioInvent Submits IND for Phase I/IIa Trial of Anti-FcγRIIB Antibody
Analytical Equipment
Manufacturing Equipment
Facility Inspection/License Status
Phone:+46 (0)46-286 85 50
Fax:+46 (0)46-211 08 06
Email:[email protected]
Website:http://www.bioinvent.com/
Address:Ideon Science Park SE-223 70 Lund
+46 (0)46-286 85 50Fax:
+46 (0)46-211 08 06Email:
[email protected]Website:
http://www.bioinvent.com/Address:
Ideon Science Park SE-223 70 Lund